据报道,用丙炔苯丙胺阻滞乙型单胺氧化酶(MAO-B),可延缓帕金森病病程的发展。试验结果表明,甲苯四氢吡啶(MPTP)是在其被 MAO-B 转变为甲苯吡啶阳离子(MPP~+)后才引起帕金森综合征的。因此,MAO-B 似乎对特发性和 MPTP 诱发的帕金森病神经机能障碍的发病机理均起着决定性的作用。作者曾用苯乙胺作底物测定单胺氧化酶(MAO),发现未经治疗的帕金森病患者其催化活性增加。这可能有许多原因,包括由于其病程或病因所致的合成 It has been reported that blockade of monoamine oxidase (MAO-B) with bupropion slows down the progression of Parkinson’s disease. The experimental results show that toluene tetramethylpyridine (MPTP) is Parkinson’s syndrome caused by the conversion of MAO-B to tolylpyridinium cation (MPP ~ +). Therefore, MAO-B appears to play a decisive role in the pathogenesis of idiopathic and MPTP-induced Parkinson’s disease neurological disorders. The authors used phenethylamine as a substrate for the determination of monoamine oxidase (MAO) and found that their catalytic activity was increased in untreated Parkinson’s disease patients. There are many possible reasons for this, including the synthesis due to its duration or etiology